Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ DR4 Monoclonal Antibody (32A1380)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA125373
Description
MA1-25373 detects TRAIL Receptor 1 from human samples.
TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).
Specifications
DR4 | |
Monoclonal | |
0.5 mg/mL | |
PBS with 0.05% sodium azide | |
O00220 | |
TNFRSF10A | |
Synthetic peptide corresponding to residues 1-20 of human TRAIL Receptor 1. | |
50 μg | |
Primary | |
Human | |
Antibody | |
IgG1 |
Flow Cytometry, Western Blot, Immunocytochemistry | |
32A1380 | |
Unconjugated | |
TNFRSF10A | |
APO2; CD261; cytotoxic TRAIL receptor; death receptor 4; DR4; MGC9365; sCD261; soluble CD261; soluble TRAIL; sTRAIL; TNF receptor superfamily member 10a; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAIL receptor 1; TRAILR1; TRAIL-R1; TRAILR-1; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily member 10a variant 2; tumor necrosis factor receptor superfamily, member 10a | |
Mouse | |
Protein G | |
RUO | |
8797 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction